- Molecular NameClopidogrel
- SynonymNA
- Weight321.828
- Drugbank_IDDB00758
- ACS_NO113665-84-2
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.87
- pka5.6
- LogD (pH=7, predicted)3.87
- Solubility (experiment)0.05078 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.18
- LogSw (predicted, AB/LogsW2.0)0.1
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors0
- No.of HBond Acceptors3
- No.of Rotatable Bonds4
- TPSA57.78
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
- Absorption_value50.0
- Absorption (description)After oral administration, clopidogrel is rapidly, but incompletely (approx. 50%), absorbed.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding98.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is extensively metabolised in the liver to produce two metabolites, the main circulating metabolite (85%) being the inactive carboxylic acid derivative. Clopidogrel is oxidised to 2-oxo-clopidogrel with further hydrolysis to produce the active thiol derivative, which has not yet been identified in plasma.
- Half lifeThe elimination half-life of the inactive metabolite is approx. 8 h.
- ExcretionClopidogrel and its metabolites are equally excreted in urine and faeces.
- Urinary ExcretionN/A
- Clerance10 mg/L/h
- ToxicityA single case of deliberate overdose, during clinical trials, has been reported. A 34-year-old woman swallowed a single dose of 1050 mg (equivalent to 14 standard 75 mg tablets) clopidogrel with no associated undesirable effects. No special therapy was needed.
- LD50 (rat)N/A
- LD50 (mouse)N/A